Last 7 YEAR cml undetacktable......
MY question....
1, How long time undetacktable possible?
2, life long possible? (undetacktable) (lower dose)
3, IMTINIB Failure possible after many years (7+) undetacktable
I am worried about TKI failure in future
ONE article says miristen 126 cure cml ( permanent remission) (june 2018) in future......
But no update available last 7-8 months
In Google.......
Vikram,
Undetectable doesn't mean gone. With advances in PCR technology, an old undetectable result may be detectable in the future even with no change in disease.
So don't worry about undetectable. All you need is results below 0.1%. With low results, there is no reason you or any other CML patient will maintain this response life-long. It is possible, but very unlikely, to develop resistance in the future but of course there are other drugs available. But I must stress that this is very unlikely. People who achieve low PCR results almost always maintain them, and some are even lucky enough that they can maintain them treatment-free.
If your most recent PCR result was undetectable, stop worrying and enjoy your life. It will be a long one!
David.
Imtinib eliminated leukemia cell but not eliminated leukemia stems cell.....
After 10 year treatment.....
Lsc automatically eliminate possible.....
Any chance...........?
Full cure possible?
Near future ( 2020_2022)
MIR 126 HUMANS TRAIER?
ONE ARTICLE SAYS MIRISTEN 126 TARGET LSC CELL. ELIMINATE ALL LSC CELL ( MICE)
ANY UPDATE
MIR 126
PLEASE REPLY.................
Undetacktable (<0.0001)
No detected cell in test?
Means 1 luckemia cell 1000000?
1 luckemia cell 100000?
How many lsc (luckemia stem cell)?
MD Anderson testing a drug called venetoclax. Check that out. To be used in conjunction with your tki in testing now.
Steff
https://www.targetedonc.com/news/fda-puts-enrollment-hold-on-venetoclax-...
"The clinical hold does not affect any of the FDA-approved indications for venetoclax, which include the treatment of patients with chronic lymphocytic leukemia and acute myeloid leukemia. The hold also does not impact clinical studies of the BCL-2 inhibitor for patients with malignancies other than myeloma."
@onekayaker
Releated to this trial https://clinicaltrials.gov/ct2/show/NCT02689440 I wrote to Dr Kantarjian about results. He replied me that there are still no results for that.
Regarding hold on venetoclax that was due increased no. of death against control group: https://www.clinicaloncology.com/Hematologic-Malignancies/Article/03-19/...
There were 291 patients included in the analysis. The median follow-up was approximately 17.9 months. At the interim analysis for overall survival, there were 41 deaths among 194 patients (21.1%) in the venetoclax investigational arm and 11 deaths among 97 controls (11.3%) in the placebo arm. The hazard ratio (HR) of the venetoclax arm to the placebo arm was 2.03 (95% CI, 1.04-3.94), showing an approximately twofold increased risk for death over the placebo arm.
That was for https://clinicaltrials.gov/ct2/show/NCT02755597
